Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06906341 · ClinicalTrials.gov registry record · Phase 2
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
A Phase 2 study of Ovarian Cancer and Endometrial Cancer, sponsored by Corcept Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 270
- Enrollment target
- 20
- Study locations
NCT06906341: Recruiting Phase 2 study of Ovarian Cancer and Endometrial Cancer, sponsored by Corcept Therapeutics.
NCT06906341 is a Phase 2 study of Ovarian Cancer and Endometrial Cancer that is actively recruiting participants, run by Corcept Therapeutics. The registered enrollment target is 270 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06906341, a Phase 2 study of Ovarian Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Corcept Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 270 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
Primary Outcome
To evaluate PFS as the time from enrollment until first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator, or death due to any cause, whichever occurs first.
Conditions Studied
Interventions
- DRUG Relacorilant 150 mg once daily (QD)
- DRUG Nab-paclitaxel 80 mg/m^2
- DRUG Bevacizumab 10 mg/kg
Study Locations (20)
Other
- 328 - Aalst
- 326 - Charleroi
- 325 - Hasselt
- 108 - Leuven
- 306 - Lille
- 307 - Nancy
California
- 150 - Palo Alto
- 014 - San Francisco
Florida
- 544 - Fort Myers
- 543 - West Palm Beach
Missouri
- 334 - Kansas City
- 521 - St Louis
Virginia
- 522 - Fairfax
- 300 - Norfolk
Minnesota
- 518 - Minneapolis
New Mexico
- 292 - Albuquerque
Ohio
- 304 - Centerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2025-04-11 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT06906341 shows while recruiting
NCT06906341 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (63% lower).
The record links to 4 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which Relacorilant 150 mg once daily (QD) is the first listed.
NCT06906341 names 20 study sites across 11 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06906341 about?
NCT06906341 is a clinical study titled "Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers". This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
What is the current status of trial NCT06906341?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 2025-04-11. Estimated completion is 2026-12.
What conditions does trial NCT06906341 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms.
What interventions are being tested in trial NCT06906341?
The interventions under investigation include: Relacorilant 150 mg once daily (QD) (DRUG), Nab-paclitaxel 80 mg/m^2 (DRUG), Bevacizumab 10 mg/kg (DRUG).
Who is sponsoring clinical trial NCT06906341?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06906341 being conducted?
This trial has 20 study locations across California, Florida, Minnesota, Missouri, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06906341's enrollment target sits among peer trials
270 78th of 322 higher than 245 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI